β受体阻滞剂在高血压应用中的专家共识

2019-04-20 中国心血管相关专家小组(统称) 《中国医学前沿杂志(电子版)》.2019,11(4):29-39.

近年来,国内外几部重要的高血压指南陆续更新,一些新的循证证据和荟萃分析比较了各类降压药物的降压疗效及对心脑血管事件的影响。基于此,本共识专家组经反复讨论,达成一致意见并撰写《β受体阻滞剂在高血压应用中的专家共识》,旨在推动β受体阻滞剂在我国高血压患者中的合理应用。

中文标题:

β受体阻滞剂在高血压应用中的专家共识

发布日期:

2019-04-20

简要介绍:

近年来,国内外几部重要的高血压指南陆续更新,一些新的循证证据和荟萃分析比较了各类降压药物的降压疗效及对心脑血管事件的影响。基于此,本共识专家组经反复讨论,达成一致意见并撰写《β受体阻滞剂在高血压应用中的专家共识》,旨在推动β受体阻滞剂在我国高血压患者中的合理应用。

拓展指南:高血压相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=β受体阻滞剂在高血压应用中的专家共识)] GetToolGuiderByIdResponse(projectId=1, id=db1b51c001e35a71, title=β受体阻滞剂在高血压应用中的专家共识, enTitle=, guiderFrom=《中国医学前沿杂志(电子版)》.2019,11(4):29-39., authorId=null, author=, summary=近年来,国内外几部重要的高血压指南陆续更新,一些新的循证证据和荟萃分析比较了各类降压药物的降压疗效及对心脑血管事件的影响。基于此,本共识专家组经反复讨论,达成一致意见并撰写《β受体阻滞剂在高血压应用中的专家共识》,旨在推动β受体阻滞剂在我国高血压患者中的合理应用。 , cover=, journalId=null, articlesId=null, associationId=306, associationName=中国心血管相关专家小组(统称), associationIntro=本制定者非特指某个专家小组,为统称。, copyright=0, guiderPublishedTime=Sat Apr 20 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>近年来,国内外几部重要的高血压指南陆续更新,一些新的循证证据和荟萃分析比较了各类降压药物的降压疗效及对心脑血管事件的影响。基于此,本共识专家组经反复讨论,达成一致意见并撰写《β受体阻滞剂在高血压应用中的专家共识》,旨在推动β受体阻滞剂在我国高血压患者中的合理应用。</div> <div><br> </div>拓展指南:<strong>与<font color=red>高血压</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=2f25a1c001e263f3" title="2019 中国指南:老年高血压的管理—英文版" target=_blank>2019 中国指南:老年高血压的管理—英文版</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ebc471c001e237f4" title="中国实体器官移植术后高血压诊疗规范(2019版)" target=_blank>中国实体器官移植术后高血压诊疗规范(2019版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=acf441c001e210ac" title="2019 AAS/EFAS/ESH科学声明:神经原性直立性低血压患者仰卧位高血压的管理" target=_blank>2019 AAS/EFAS/ESH科学声明:神经原性直立性低血压患者仰卧位高血压的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=1b8b61c001e151fa" title="中国专家建议:中国高血压患者盐摄入和血压管理(英文版)" target=_blank>中国专家建议:中国高血压患者盐摄入和血压管理(英文版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=5436a1c001e1a922" title="中国老年高血压管理指南2019" target=_blank>中国老年高血压管理指南2019</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E9%AB%98%E8%A1%80%E5%8E%8B" target=_blank>有关高血压更多指南</a></ul>, tagList=[TagDto(tagId=893, tagName=β受体阻滞剂), TagDto(tagId=274, tagName=高血压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4625, appHits=563, showAppHits=0, pcHits=2789, showPcHits=2103, likes=85, shares=20, comments=4, approvalStatus=1, publishedTime=Wed May 08 23:16:18 CST 2019, publishedTimeString=2019-04-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed May 08 23:16:18 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 03:57:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=β受体阻滞剂在高血压应用中的专家共识)])
β受体阻滞剂在高血压应用中的专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=912169, encodeId=430c91216904, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09472501984, createdName=1249f2d7m58暂无昵称, createdTime=Wed Dec 30 15:04:25 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369399, encodeId=d59436939957, content=β受体, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4632552309, createdName=12545189m83(暂无昵称), createdTime=Wed Jul 10 09:57:03 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366326, encodeId=bf433663262c, content= 好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiajLbAsAueF1jnBKqhVyc4pP8QMMccWppia8wXgHBSZs21sflPe3n22WgzFDKjKwiadDsVP7nQTdgQ/132, createdBy=2ada1637844, createdName=bear0815, createdTime=Fri May 17 01:26:30 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2020-12-30 1249f2d7m58暂无昵称

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=912169, encodeId=430c91216904, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09472501984, createdName=1249f2d7m58暂无昵称, createdTime=Wed Dec 30 15:04:25 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369399, encodeId=d59436939957, content=β受体, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4632552309, createdName=12545189m83(暂无昵称), createdTime=Wed Jul 10 09:57:03 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366326, encodeId=bf433663262c, content= 好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiajLbAsAueF1jnBKqhVyc4pP8QMMccWppia8wXgHBSZs21sflPe3n22WgzFDKjKwiadDsVP7nQTdgQ/132, createdBy=2ada1637844, createdName=bear0815, createdTime=Fri May 17 01:26:30 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-07-10 12545189m83(暂无昵称)

    β受体

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=912169, encodeId=430c91216904, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09472501984, createdName=1249f2d7m58暂无昵称, createdTime=Wed Dec 30 15:04:25 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369399, encodeId=d59436939957, content=β受体, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4632552309, createdName=12545189m83(暂无昵称), createdTime=Wed Jul 10 09:57:03 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366326, encodeId=bf433663262c, content= 好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiajLbAsAueF1jnBKqhVyc4pP8QMMccWppia8wXgHBSZs21sflPe3n22WgzFDKjKwiadDsVP7nQTdgQ/132, createdBy=2ada1637844, createdName=bear0815, createdTime=Fri May 17 01:26:30 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-17 bear0815

    好好学习

    0